ALK and non-small cell lung carcinoma: Non-small cell lung cancer with mutations of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) mutations, ROS proto-oncogene 1 (ROS1) rearrangement, mesenchymal-epithelial transition (MET) factor amplification, v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutations, human epidermal growth factor receptor 2 (HER2) mutations, and RET rearrangement respond well to treatment (75).